Someone buying into SYN again.

Merck and tau.
http://www.mrknewsroom.com/news-release/corporate-news/merck-enters-exclusive-worldwide-license-agreement-teijin-pharma-investi

Some fund bought in.

BCRX is on fire due to data release. This stock was 13 in 09.

Story of my life I bought some warrants before they anounced data. Well the data was not good. It took a big drop. This was the second time they failued so I don't know why the warrants are moving up?

I wonder why OPAXW has been moving up over the last several days?

Wake up! http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0177914

BLPH 8k- Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference: https://globenewswire.com/news-release/2017/05/22/994854/0/en/Positive-Clinical-Data-on-INOpulse-Presented-at-the-American-Thoracic-Society-113th-International-Conference.html

BLPH 8k- Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference: https://globenewswire.com/news-release/2017/05/22/994854/0/en/Positive-Clinical-Data-on-INOpulse-Presented-at-the-American-Thoracic-Society-113th-International-Conference.html

Maxim Group llc upgrades BLRX for hold to buy.

LJPC anyone know why it is running?

BLPH. RIEF-CVI Investments reports 5.7 percent passive stake in Bellerophon Therapeutics as of May 10
BY Reuters
— 11:49 AM ET 05/18/2017
May 18 (Reuters) - CVI Investments Inc
* CVI Investments Inc reports 5.7 percent passive stake in Bellerophon Therapeutics Inc ( BLPH
Loading...
Loading...
) as of May 10, 2017 - SEC filing Source text : [ID:http://bit.ly/2pPdxAg] Further company coverage:
Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world

http://www.fiercepharma.com/special-report/top-15-generic-drugmakers-2016?mkt_tok=eyJpIjoiTnpobVpUZGpPV0k1T1RkayIsInQiOiJIeDVUakFSQVlkeTlMRDJRcEQ0Tzhyc3BPY2FFWkNRYjlGVnZDc2lSWnZnOGc4ZGJLZ01BcE1uYnk5MlJKTFdsRTVtOSs1bDJEakUyK25QSWFCd2tpd0h1MTlqNDJnRzA1VmxCMnhOZTd3Vk5SeUhFY3RkTllkXC9CWCtHNGJXNjYifQ%3D%3D&mrkid=1001335&utm_medium=nl&utm_source=internal

Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the July 9, 2012 Food and Drug Administration Safety and Innovation Act.[1][2] The FDA acknowledges that the designation is not intended to imply that the drug is actually a "breakthrough".[3] It allows the FDA to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases.[4][5][6] The FDA has other mechanisms for expediting the review and approval process for promising drugs, including fast track designation, accelerated approval, and priority review.[7]
Contents
1 Requirements
2 Incentives
3 Issues
4 See also
5 References
Requirements
A breakthrough therapy designation can be assigned to a drug if "it as a drug which is intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition" and if the preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development."[8]
Requests are reviewed by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). CDER receives approximately 100 requests per year for breakthrough designation. Historically, about one third were approved. CBER receives 15-30 requests per year.[9] Sponsors must apply for breakthrough status separately for each indication they intend to label the drug for.
Breakthrough designation applications are submitted as an amendment to the IND applications before the initiation of clinical trials.[10]
Incentives
Drugs that have been granted breakthrough status are given priority review. The FDA will work with the sponsor of the drug application to expedite the approval process. This can include rolling reviews, smaller clinical trials, and alternative trial designs.[11]

SYN got break thorough therapy designation.

PTX up again on heavy vol.

Very good day for PTX! Broke 5 and 6 in AH.

Scott Hennessy
Account Manager at Avalanche Enterprise Ltd
Pernix Therapeutics Holdings: The End Is Near
April 26, 2017 • 7 Likes • 1 Comment

In a recent article I outlined my case for why Pernix Therapeutics Holdings (PTX) is a suitable and favourable buyout target based on fundamental and technical analysis. Since John Sedor took the CEO position, the thesis has developed into a real possibility with substantial evidence and events pre-empting my interpretation that this company is severely undervalued and holds significant upside potential from it's current trading price of $3.95.

However, the longs have been screaming buyout since September 2016 when rumours circulated that the company was being bought imminently. Severn months later and with no buyout announcement as of yet, the stock has suffered day to day fluctuations which indicate that day traders are in control. It should be noted though that the stock is up 104% since it's $1.94 low on December 27th 2016.

A recent 8k filing and communication from John Sedor himself in the Q4 full results and conference call has led me to believe that a buyout THIS time is literally around the corner, by July 31st to be exact. Lets start with the 8k. The company filed documents last week with the SEC regarding details of an amendment to it's credit facility with Wells Fargo. Again the document is littered with buyout hints as a result of the legal, profound and style of communication that the document is written in. It's not just retail investors that are getting excited about this, the increase in institutional ownership has grown double digits with short interest declining; creating an increase in investor sentiment.

Without going into intricate detail of the material released in the 8k, there are a few essential points to identify and explain that adds to my buyout thesis. The common theme of the 8k detailed how the potential of an investment bank would partner with Pernix Therapeutics Holdings to assist the company ''with the marketing, negotiation, documentation and consummation of an acceptable sale'' , as well as outlining certain terms based around the outcomes of a buyout with regards to the credit agreement with Wells Fargo.

The 8k was released Thursday after hours, with the stock spiking 40% in the early hours of opening on Friday morning. Granted the stock sold off as a result of day traders locking in their profits, but for the long term fundamental investors; these signs are taken with a sense of prosperity and positivity.

Whats next?

The next big catalyst for the bull theory is the official announcement of an acquisition. Shareholders are looking for a substantial premium to current trading prices, with some analysts stating $30 is a fair valuation. However with the potential of Silenor OTC, sequential Q on Q sales growth, John Sedor's glittered company buyout history, relaxed litigation payments to GSK, increased institutional ownership, this stock is poised for lift off imminently. The stock is trading on bankruptcy levels and beaten down sentiment, which is largely unfair, however a wise investor will understand that the value and potential of Pernix's assets in the hands of big pharma far outweigh the net debt value, creating extraordinary value for shareholders in the process.

If anyone wants to chat about value investing, stocks or business in general; please feel free to reach out and drop me a message!

Scott Hennessy

I am a seriously hurting puppy!

Come on PTX get the bo done already! Getting ready to go in for my 6th back surgery in a few minutes. Had my 5th the 18th. Please keep me in your prayers! Been a very miserable week. Thanks

Who are the Jesselsons?

July 14

I am still holding from 2m pre split.

I finally got my Zohydro ER filled. All the other 20 or so that I called or checked were on back order till May. I called Pernix, they have a locator service. Took them about 2 hours put they found a pharmacy that had it. They also have a coupon if you need it. $650 if I had to pay for it.

People forgot about 15m paid out to GSK.

PTX up 9.5% before the bell.

PTX earning tomorrow after the close. Hoping for 42m plus.

PTX earning tomorrow after the close. Hoping for 42m plus.

Read my thread just posted on ST. I don't feel like retyping it on my phone. http://stocktwits.com/buckiii2/message/78524632

PM me if you can.

My Avg is DOWN to 1.29. How many percent will that take to get even?

He just went back in his office for a few minutes and came back out with the script. He was concerned that this would not work for sudden pain flare ups. I do not have that issue. My back nerve pain is 24/7.

Ha yes. I wonder if anything ever progressed with that Battery?

You are reading it wrong. That is just saying that those companies have trails in the same area as to what ILNS is researching. If they had deals or partnerships there would have been news releases and SEC 8k filings. Sorry to bust your bubble. My investment in this company is down 90 some percent. I have pretty much written it off as a loss. Not selling, why sell for pennies. I guess there is still hope they are not bankrupt yet. Maybe one day we will wake up to outstanding news who knows?

ILNS has no deal with either of those two companies. You got my heart beat up for a couple minutes.The Web site has been re tooled since I looked at it.

FWIW I got my pain management Dr to write me a script for Zohydro ER instead of regular hydrocodone. I had to show it to him on my cell phone, he had not heard about it. I called about 10 CVS/Walgreens, noone had it in stock. Did not come in today still waiting. Hopefully it doesn’t cost me anything. I have 2 insurances. So I did my part to get the stock price up ha ha. Hopefully it works better.

Since when did these other two companies come into play with ILNS? How did I miss that? Those two companies are huge.

PTX broke 4.oo on high volume.

Hopefully this is good for PTX. http://www.biopharmadive.com/news/fda-advisory-panel-votes-against-endos-opioid-painkiller/438170/

Dang it. BLPH